FDA Panel to Decide on Approval of Grail's Multi-Cancer Blood Test
publishers 2articles 2first reported 23 Sep, 10:00 UTCdeveloping since 23 Sep · 4 editions
An independent panel of experts will vote on whether to recommend Grail's Galleri blood test for FDA approval. The test claims to detect up to 50 forms of cancer from a single blood draw, according to NPR News. However, a major study cited by MarketWatch Top Stories failed to prove that the test could effectively detect later-stage cancers. The outcome of the FDA panel's vote will influence whether Medicare and other health insurers cover the test. Grail has not yet provided specific details on the results of the study or how the test might be improved based on its findings. The decision by the FDA panel will be a critical step in determining the test's future in the healthcare system.
HOW THIS STORY WAS MADE
Written from 2 articles, 1 with the publisher's own text; 2 independent newsrooms once syndicated copies count as one.
- Publishers
- 2
- Source articles
- 2
- Given to the writer
- 2, 1 with the article's own text
- Independent newsrooms
- 2
- Publication gate
- passed
- Human review
- none
Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →